Alpha IMS (Retina Implant AG) receives CE mark approval in the EU for Retinitis Pigmentosa

Retina Implant AG's wireless subretinal implant technology, the Alpha IMS, has received CE Mark approval in the EU to treat Retinitis Pigmentosa. To date, 36 patients have received the Alpha IMS microchip. This is the first European regulatory certification for the Company and the Alpha IMS device.

Results from Retina Implant AG's second human clinical trial were published in Proceedings of the Royal Society B in February 2013, showing that patients with the Alpha IMS chip were able to recognise faces and read signs. Results from the first human clinical trial, published in Proceedings of the Royal Society B in 2010 showed that placement of the implant beneath the fovea provided optimum visual results, allowing patients to recognize objects and facial expressions as well as read words.